Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...
BAAR, Switzerland, March 02, 2026--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua ® through the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results